|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0025202,
umls-concept:C0025241,
umls-concept:C0031001,
umls-concept:C0034693,
umls-concept:C0034721,
umls-concept:C0086418,
umls-concept:C0205409,
umls-concept:C0348080,
umls-concept:C0522537,
umls-concept:C1280500,
umls-concept:C1522391,
umls-concept:C1549542,
umls-concept:C1704689,
umls-concept:C1704711
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
1997-5-2
|
|
pubmed:abstractText |
An isolated rat hindlimb perfusion model carrying xenografts of the human melanoma cell line MM96 was used to study the effects of perfusion conditions on melphalan distribution. Krebs-Henseleit buffer and Hartmann's solution containing 4.7% bovine serum albumin (BSA) or 2.8% dextran 40 were used as perfusates. Melphalan concentrations in perfusate, tumour nodules and normal tissues were measured using high-performance liquid chromatography (HPLC). Increasing the perfusion flow rates (from 4 to 8 ml min(-1)) resulted in higher tissue blood flow (determined with 51Cr-labelled microspheres) and melphalan uptake by tumour and normal tissues. The distribution of melphalan within tumour nodules and normal tissues was similar for both Krebs-Henseleit buffer and Hartmann's solution; however, tissue concentrations of melphalan were significantly higher for a perfusate containing 2.8% dextran 40 than for one containing 4.7% BSA. The melphalan concentration in the tumour was one-third of that found in the skin if the perfusate contained 4.7% BSA. In conclusion, this study has shown that a high perfusion flow enhances the delivery of melphalan into implanted tumour nodules and normal tissues, and a perfusate with low melphalan binding (no albumin) is preferred for maximum uptake of drug by the tumour.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/9099965-1389515,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9099965-1637666,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9099965-2379595,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9099965-3103506,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9099965-3360151,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9099965-3360157,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9099965-3400246,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9099965-3701643,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9099965-3978538,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9099965-5169948,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9099965-572542,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9099965-6163526,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9099965-641810,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9099965-6727389,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9099965-7500271,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9099965-7699574,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9099965-7703715,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9099965-7802575,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9099965-7899249,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9099965-8018528,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9099965-8038596,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9099965-8138892,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9099965-8209941,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9099965-830403,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9099965-8611961,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9099965-877305
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
75
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1160-6
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:9099965-Animals,
pubmed-meshheading:9099965-Antineoplastic Agents, Alkylating,
pubmed-meshheading:9099965-Cell Transplantation,
pubmed-meshheading:9099965-Chromatography, High Pressure Liquid,
pubmed-meshheading:9099965-Glucose,
pubmed-meshheading:9099965-Hindlimb,
pubmed-meshheading:9099965-Humans,
pubmed-meshheading:9099965-Isotonic Solutions,
pubmed-meshheading:9099965-Male,
pubmed-meshheading:9099965-Melanoma,
pubmed-meshheading:9099965-Melphalan,
pubmed-meshheading:9099965-Organ Preservation Solutions,
pubmed-meshheading:9099965-Perfusion,
pubmed-meshheading:9099965-Rats,
pubmed-meshheading:9099965-Rats, Nude,
pubmed-meshheading:9099965-Transplantation, Heterologous,
pubmed-meshheading:9099965-Tromethamine,
pubmed-meshheading:9099965-Tumor Cells, Cultured
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
The effects of perfusion conditions on melphalan distribution in the isolated perfused rat hindlimb bearing a human melanoma xenograft.
|
|
pubmed:affiliation |
Department of Medicine, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
